These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32046620)

  • 1. Eradication of
    Akkerman-Nijland AM; Yousofi M; Rottier BL; Van der Vaart H; Burgerhof JGM; Frijlink HW; Touw DJ; Koppelman GH; Akkerman OW
    Ther Adv Respir Dis; 2020; 14():1753466620905279. PubMed ID: 32046620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.
    Geller DE; Weers J; Heuerding S
    J Aerosol Med Pulm Drug Deliv; 2011 Aug; 24(4):175-82. PubMed ID: 21395432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
    Treggiari MM; Rosenfeld M; Mayer-Hamblett N; Retsch-Bogart G; Gibson RL; Williams J; Emerson J; Kronmal RA; Ramsey BW;
    Contemp Clin Trials; 2009 May; 30(3):256-68. PubMed ID: 19470318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled antibiotics for lower airway infections.
    Quon BS; Goss CH; Ramsey BW
    Ann Am Thorac Soc; 2014 Mar; 11(3):425-34. PubMed ID: 24673698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dry powder inhalation containing muco-inert ciprofloxacin and colistin co-loaded liposomes for pulmonary P. Aeruginosa biofilm eradication.
    Wang J; Guo Y; Lu W; Liu X; Zhang J; Sun J; Chai G
    Int J Pharm; 2024 Jun; 658():124208. PubMed ID: 38723731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis.
    Claude F; Rochat I; Hafen GM
    BMC Res Notes; 2019 Mar; 12(1):115. PubMed ID: 30832714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial.
    Mayer-Hamblett N; Retsch-Bogart G; Kloster M; Accurso F; Rosenfeld M; Albers G; Black P; Brown P; Cairns A; Davis SD; Graff GR; Kerby GS; Orenstein D; Buckingham R; Ramsey BW;
    Am J Respir Crit Care Med; 2018 Nov; 198(9):1177-1187. PubMed ID: 29890086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing the Efficacy and Safety of Nebulized Gentamicin Plus Amikacin
    Kouhestani F; Hassanzad M; Baniasadi S
    Curr Drug Saf; 2024; 19(1):82-87. PubMed ID: 36852787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhaled antimicrobial prescribing for Pseudomonas aeruginosa infections in Europe.
    Sloan CM; Sherrard LJ; Einarsson GG; Dupont LJ; Koningsbruggen-Rietschel SV; Simmonds NJ; Downey DG
    J Cyst Fibros; 2024 May; 23(3):499-505. PubMed ID: 38360460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Treggiari MM; Retsch-Bogart G; Mayer-Hamblett N; Khan U; Kulich M; Kronmal R; Williams J; Hiatt P; Gibson RL; Spencer T; Orenstein D; Chatfield BA; Froh DK; Burns JL; Rosenfeld M; Ramsey BW;
    Arch Pediatr Adolesc Med; 2011 Sep; 165(9):847-56. PubMed ID: 21893650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1).
    Loebinger MR; Polverino E; Blasi F; Elborn SJ; Chalmers JD; Tiddens HA; Goossens H; Tunney M; Zhou W; Angyalosi G; Hill AT; Haworth CS;
    Pulm Pharmacol Ther; 2019 Oct; 58():101834. PubMed ID: 31433997
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Li Z; Barnaby R; Nymon A; Roche C; Koeppen K; Ashare A; Hogan DA; Gerber SA; Taatjes DJ; Hampton TH; Stanton BA
    Am J Physiol Lung Cell Mol Physiol; 2024 May; 326(5):L574-L588. PubMed ID: 38440830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALPINE2: Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis.
    Gilchrist FJ; Bui S; Gartner S; McColley SA; Tiddens H; Ruiz G; Stehling F; Alani M; Gurtovaya O; Bresnik M; Watkins TR; Frankovic B; Skov M;
    J Cyst Fibros; 2024 Jan; 23(1):80-86. PubMed ID: 37455237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and characterization of a spray-dried inhalable ternary combination for the treatment of Pseudomonas aeruginosa biofilm infection in cystic fibrosis.
    Alhajj N; Yahya MFZR; O'Reilly NJ; Cathcart H
    Eur J Pharm Sci; 2024 Jan; 192():106654. PubMed ID: 38013123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of aminoglycoside antibiotic serum concentrations collected by peripheral veins and peripherally inserted central catheters in adults with cystic fibrosis.
    Sherwood SJ; Tak C; Bhakta ZN; Packer K; Jacobs H; Liou TG; Young DC
    Pediatr Pulmonol; 2024 Jun; 59(6):1740-1746. PubMed ID: 38501330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experience with nebulised colistin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa].
    López-Gil Otero MM; Romero-Ventosa EY; Feijoo-Meléndez D; Casanova-Martínez C; Otero-Millán L; Piñeiro-Corrales G
    Rev Esp Quimioter; 2019 Jun; 32(3):217-223. PubMed ID: 30924621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudomonas aeruginosa aggregation and Psl expression in sputum is associated with antibiotic eradication failure in children with cystic fibrosis.
    Morris AJ; Yau YCW; Park S; Eisha S; McDonald N; Parsek MR; Howell PL; Hoffman LR; Nguyen D; DiGiandomenico A; Rooney AM; Coburn B; Grana-Miraglia L; Wang P; Guttman DS; Wozniak DJ; Waters VJ
    Sci Rep; 2022 Dec; 12(1):21444. PubMed ID: 36509824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility study to inform the design of a randomised controlled trial to eradicate Pseudomonas aeruginosa infection in individuals with cystic fibrosis.
    Hickey HR; Jones AP; Lenney W; Williamson PR; Smyth RL
    Trials; 2010 Feb; 11():11. PubMed ID: 20137079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eradication treatment for
    Conceição M; Shteinberg M; Goeminne P; Altenburg J; Chalmers JD
    Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38296344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinafloxacin for Treatment of Burkholderia cenocepacia Infection in a Cystic Fibrosis Patient.
    Balwan A; Nicolau DP; Wungwattana M; Zuckerman JB; Waters V
    Antimicrob Agents Chemother; 2016 Jan; 60(1):1-5. PubMed ID: 26722110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.